Idt Australia Limited · ASX:IDT
Idt Australia — FY2023 Earnings Presentation
21 slides from Idt Australia's earnings presentation, Aug 30, 2023
Slide 1: IDT Australia FY23 Full Year Results Presentation
1 For personal use only IDT Australia FY23 Full Year Results Presentation
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices 2 This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does n
Slide 3: Meet the Team
MEET THE TEAM 3 N E W L E A D E R S H I P T E A M Mark Simari Chairman Jane Ryan Non-Executive Director For personal use only Mark Simari is an experienced and accomplished professional in the Dr Jane Ryan was appointed as a NED in January 2022. She has over 30 years health industry and has over 15
Slide 4: Executing on Strategic Objectives
Executing on Strategic Objectives 4 F Y 2 3 A C H E I V E M E N T S For personal use only Strategic Pivot & Capture Emerging Return to Near-Term Strengthen Balance Restructuring Opportunities Profitability Sheet Develop plan to return Growing demand for Build a strong pipeline Undertake a $7
Slide 5: FY23 Results Highlights
FY23 Results Highlights 5 G R O W T H I N K E Y V E R T I C A L S For personal use only Strategic pivot to build three key verticals already Revenue from Key Business Verticals up yielding positive results 24% YoY FY23 revenue from these verticals jumped 25% YoY $14 to $6.4M and is a more accura
Slide 6: Core Business Pillars
CORE BUSINESS PILLARS 6 I D T A U S T R A L I A ’ S B U S I N E S S D I V I S I O N S For personal use only Active Pharmaceutical Ingredient (API) Finished Dosage Forms (FDFs) The active component which produces the required effect in drugs A drug product in the final form that can be administered t
Slide 7: API Manufacturing
API MANUFACTURING 7 L A R G E S T E S T A B L I S H E D L E A D E R For personal use only Deep experience in high potent small Revenue jumped 48% YoY to $1.7M molecule R&D, process design, scale and validation. • Active Pharmaceutical Products The API vertical represented 24% of Group revenue in FY2
Slide 8: Specialty Orals
SPECIALTY ORALS 8 K E Y D R I V E R O F N E A R - T E R M G R O W T H For personal use only Revenue from this vertical increased 13% YoY to $4.6M The business represented 66% of Group revenue in FY23 IDT Australia has the licensure, capabilities and facilities to manufacture a range of Well placed t
Slide 9: Specialty Orals: Additional Opportunity in Psychedelics
SPECIALTY ORALS 9 A D D I T I O N A L G R O W T H O P P O R T U N I T Y I N P S Y C H E D E L I C S The Therapeutic Goods Administration (TGA) is permitting the prescription of For personal use only MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistan
Slide 10: Advanced Therapies
ADVANCED THERAPIES 10 G R O W I N G D E M A N D & L I M I T E D S U P P L Y For personal use only Achieved revenue of $200K in FY23 Secured sterile license extension in with further growth expected over April 2023 from TGA coming periods IDT’s Aseptic Sterile Processing (ASP) facility is one of only
Slide 11: Large & Growing Addressable Markets
11 For personal use only Large & Growing Addressable Markets
Slide 12: Large Addressable Markets
LARGE ADDRESSABLE MARKETS 12 L E V E R A G E D T O M U L T I P L E L U C R A T I V E O P P O R T U N I T I E S Advanced Therapies Specialty Orals API Manufacturing For personal use only Aseptic Fill & Finish Medicinal Cannabis & (ADC & mRNA) Psychedelics API Production • TAM: Global market forecast
Slide 13: Strong Industry Growth
STRONG INDUSTRY GROWTH 13 A T L E A S T 1 5 % C A G R G R O W T H 2 0 2 3 - 2 0 2 6 1 For personal use only Base case growth forecast of 15% CAGR with bull US$ bn Biologics CDMO2 Market Growth case estimated at 25%-30% CAGR (2022-2026) (Base Case) Demand for CDMO to outpace any increase in supply de
Slide 14: Replacing Traditional Chemo
REPLACING TRADITIONAL CHEMO 14 > U S $ 1 4 0 B N O P P : M O V I N G F R O M T R A D I T I O N A L T O “ S M A R T ” C H E M O 1 For personal use only "Smart chemotherapy" is the idea of using an antibody to act as a guidance system to find a cancer, and attaching chemotherapy molecules to the antib
Slide 15: Sales Pipeline & Outlook
15 For personal use only Sales Pipeline & Outlook
Slide 16: Sales Cycle
SALES CYCLE 16 L O N G A N D G R O W I N G R E V E N U E T A I L For personal use only Product Lifecycle Pharmaceutical groups Order size typically Clients usually stick appoint IDT ahead of increases exponentially with original contract their Ph 1 clinical trials as trials progress manufacturer due
Slide 17: Long Growth Runway
LONG GROWTH RUNWAY 17 S A L E S P I P E L I N E C O N T I N U E S T O G R O W For personal use only Current Revenue Generating Projects Stage of Projects The number of SAS and Commercial contracts have increased 55% to 17 in just three months Product Lifecycle Phase 1 Phase 2 Phase 3 SAS* Commercial
Slide 18: Balance Sheet Strength
BALANCE SHEET STRENGTH 18 L A T E N T V A L U E For personal use only 30 June 2023 $000 Current assets Cash and cash equivalents 4,433 Trade and other receivables Contract assets 3,333 Cash holdings of $4.4m plus a further $2m that was 190 Inventories 1,372 received in July 2023 from the capital r
Slide 19: Outlook
OUTLOOK 19 G R O W T H M O M E N T U M I N T O F Y 2 4 & B E Y O N D For personal use only Positive outlook with stronger FY24 results expected Strong market position with all three key verticals poised to deliver further growth Advanced Plenty of room to grow sales without significant Therapi
Slide 20: Glossary
20 Glossary For personal use only ADC Antibody Drug Conjugate MDMA Methylene-dioxy-meth-amphetamine API Active Pharmaceutical Ingredient ODC Office of Drug Control ASP Aseptic Sterile Processing PTSD Post Traumatic Stress Disorder CDMO Contract Development & Manufacturing Organisation SAS Special Ac
Slide 21: IDT Australia
For personal use only IDT Australia 21